Iomab-B SIERRA trial results accepted for oral presentation at the European Hematology Association 2023 Congress
Stockholm, May 15 , 2023 – Immedica’s partner Actinium Pharmaceuticals, Inc. has announced that an abstract on the Iomab-B SIERRA trial results has been accepted for an oral presentation at the upcoming European Hematology Association 2023 Congress (EHA) which will be held in Frankfurt, Germany, June 8-11, 2023. The abstract includes data from Actinium's controlled phase 3 study, SIERRA , comparing the efficacy of Iomab-B based conditioning, a first-in-class targeted radiotherapy, versus physician's choice of conventional care in patients ≥55 years of age with relapsed/refractory acute